Sign in
Taking people in PolandPhase 3

Compares two medicine combinations for newly diagnosed chronic lymphocytic leukemia

Tests acalabrutinib with obinutuzumab against venetoclax with obinutuzumab in adults newly diagnosed with leukemia.

Key facts

Who runs it
Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego
Where
Bia?ystok, Gdansk, Legnica, Łódź, Walbrzych, Warsaw, and Wroc?aw, PolandSee the 7 sites
Registry title
AVO-CLL: a phase III multicenter, randomized, open-label, clinical trial comparing efficacy and safety of acalabrutinib in combination with obinutuzumab versus venetoclax in combination with obinutuzumab in the first-line treatment of newly diagnosed patients with chronic lymphocytic leukemia
Status
Recruiting
Phase
Phase 3
People taking part
72 people, planned
Started
1 Jul 2024
Expected to end
1 Nov 2029
Type of study
Interventional
Record updated
18 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic lymphocytic leukemia (CLL) who have never been treated and now need treatment.

Age
Over 18 years
Sex
Women and men
Disease stage
Newly diagnosed CLL with no earlier treatment, who meet the IWCLL 2018 criteria to start treatment. ECOG performance score of 2 or lower.
Earlier treatment
No earlier systemic treatment for CLL.
Biomarker or test result
Leukemia cells that carry the markers CD19, CD20, CD23 and CD5. Negative test for HBsAg and HBcAg.

Main reasons for not taking part

  • Any earlier systemic treatment for CLL
  • Lymphoma or leukemia in the central nervous system, prolymphocytic leukemia, or Richter's syndrome
  • History of HIV infection
  • Serious heart disease, or a stroke or bleeding in the skull within 6 months
  • Another cancer, unless it was treated and has been inactive for more than 3 years

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Written informed consent to participate in a clinical trial 2. Age of patients over 18 years (women and men) 3. Diagnosis of chronic lymphocytic leukemia untreated before the screening visit 4. Presence of the following parameters during the screening period: - presence of monoclonal lymphocytes with co-expression of B cell markers (CD19, CD20 and CD23) and CD5 - prolymphocyte count <55% of peripheral blood lymphocyte count - absolute number of peripheral blood lymphocytes > 5000 /ul 5. Presence of indications to start treatment according to the International Workshop on Chronic Lymphocytic Leukemia (the National Cancer Institute-Working Group (IWCLL) 2018. 6. Laboratory test results: - absolute ANC number ≥0.75 x 109 /l or ≥0.50x109 /l in patients with documented bone marrow involvement; - platelet count ≥50x10 /l or ≥30x109 /l in patients with documented bone marrow involvement; - total bilirubin ≤1.5xULN; - AST, ALT, GGT in serum ≤3.0xULN; - estimated creatinine clearance (eGFR) ≥30 ml/min; - negative test result for HBsAg and HBcAg 7. ECOG performance assessment score ≤2. 8. Use of effective contraception by women of childbearing potential during treatment and at least 2 days after the last dose of acalabrutinib, 30 days after the last dose of venetoclax and 18 months after the last dose of obinutuzumab 9. Use of an effective form of contraception by men during the study and 90 days after taking the last dose of the IMP 10. Men must refrain from donating sperm during the study and for 90 days after taking the last dose of the study drug

Who cannot take part

  • Any previous systemic treatment for CLL 2. Diagnosis of CNS lymphoma or leukemia 3. Diagnosed prolymphocytic leukemia or previous or suspected Richter's syndrome; 4. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purple 5. Major surgery within 4 weeks before the first dose of IMP 6. Previous malignancy, except appropriately treated melanoma arising from malignant lentigo, non-melanoma skin cancer, cervical cancer “in situ”, or other treated malignancy without evidence of active disease >3 years prior to screening and at low risk of recurrence 7. Serious cardiovascular disease, e.g., uncontrolled or symptomatic arrhythmia, congestive heart failure, or myocardial infarction within 6 months before study entry, or any New York Heart Association Functional Classification class 3 or 4 heart disease or QTc >480 msec before entering the study 8. Previous stroke or intracranial hemorrhage within 6 months before randomization; 9. Current or planned anticoagulant treatment with warfarin or vitamin K antagonists within 7 days of the first dose of the study drug 10. Current or planned treatment with proton pump inhibitors 11. Current or planned treatment with a strong CYP3A inhibitor/inducer 12. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before the screening visit 13. history of HIV infection 14. History of bleeding disorders 15. The presence of contraindications to use of IMP according to Summary of Product Characteristics 16. Lack of full legal capacity 17. Lack of possibility to understand the purpose

Where in Poland

  • Uniwersytecki Szpital Kliniczny W Bia?YmstokuBia?ystok, PolandTaking people
  • Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum KliniczneGdansk, PolandTaking people
  • Wojewodzki Szpital Specjalistyczny w LegnicyLegnica, PolandTaking people
  • Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii (WWCOiT) im. M. Kopernika w ŁodziŁódź, PolandTaking people
  • Specjalistyczny Szpital Im. Dra Alfreda SokolowskiegoWalbrzych, PolandTaking people
  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i AdministracjiWarsaw, PolandTaking people
  • Dolnoslaskie Centrum Onkologii, Pulmonologii i HematologiiWroc?aw, PolandTaking people

About the trial

What the trial wants to find out

Main objective of the study: to evaluate the therapeutic efficacy, safety and tolerability of acalabrutinib in combination with obinutuzumab versus venetoclax in combination with obinutuzumab in the treatment of patients with chronic lymphocytic leukemia.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
AVO-CLL: a phase III multicenter, randomized, open-label, clinical trial comparing efficacy and safety of acalabrutinib in combination with obinutuzumab versus venetoclax in combination with obinutuzumab in the first-line treatment of newly diagnosed patients with chronic lymphocytic leukemia
Plain-language title
Compares two medicine combinations for newly diagnosed chronic lymphocytic leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
18 July 2025